Andrew Krivoshik, M.D., Ph.D.
"We must not be content only to see things as they are. We must have the vision, faith and hope to see what things can and must become."-Sister Generose Gervais
Andrew Krivoshik, M.D., Ph.D., is Frontier’s Chief Medical Officer. Andy has two decades of experience in global clinical development, biomarker strategy, translational medicine, product and patient safety, and medical affairs. Andy joined Frontier after serving as the President and Head of Development at Astellas. At Astellas, he managed all global clinical development activities and global functions. His team was responsible for the design and implementation of clinical studies aimed at new or improved products, and he was accountable for the clinical development and regulatory submissions of new medicines including enzalutamide, gilteritinib, roxadustat, enfortumab vedotin, fezolinitant, and zolbetuxumab.
Prior to joining Astellas, Andy was a Senior Medical Director at Abbott and was a graduate of the Abbott Physician Development Program. As a pharmaceutical physician, he led and managed global multidisciplinary cross functional teams, successfully implemented novel and innovative clinical trial designs, and functioned as a subject matter expert and primary author of clinical protocols, investigator brochures and regulatory submissions spanning the life cycle of clinical development including IND and NDA/MAA filings.
Andy holds a B.S.E. in Electrical Engineering with honors from Princeton University, an M.D. from the University of Illinois at Chicago (UIC) College of Medicine at Urbana-Champaign, and a Ph.D., in biophysics and computational biology from the University of Illinois at Urbana-Champaign. He received his clinical internship and residency training in pediatric and adolescent medicine at Mayo Clinic, and clinical pediatric hematology and oncology fellowship training at Duke University. He is licensed in multiple jurisdictions as both a physician and professional engineer.